-       Report 
   - February 2024
    -  70 Pages 
    New Zealand
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    New Zealand
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  90 Pages 
    Asia Pacific
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  80 Pages 
    Europe
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  90 Pages 
    South Korea
   
   From       €4269EUR$4,750USD£3,744GBP 
                 -       Report 
   - February 2024
    -  70 Pages 
    Indonesia
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    Philippines
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    India
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  90 Pages 
    United States
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  90 Pages 
    France
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    United Kingdom
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - February 2024
    -  70 Pages 
    Russia
   
   From       €4269EUR$4,750USD£3,744GBP 
                -       Report 
   - October 2022
    -  70 Pages 
    Africa
   
   From       €4269EUR$4,750USD£3,744GBP 
                  -       Report 
   - May 2024
    -  128 Pages 
    Global
   
   From       €4965EUR$5,524USD£4,354GBP 
      €5841EUR$6,499USD£5,123GBP 
                -       Report 
   - August 2024
    -  80 Pages 
    Japan
   
   From       €3146EUR$3,500USD£2,759GBP 
                -       Report 
   - May 2023
    -  147 Pages 
    Global
   
   From       €4448EUR$4,949USD£3,901GBP 
                -       Report 
   - February 2024
    -  88 Pages 
    Global
   
   From       €3500EUR$4,171USD£3,177GBP 
             
         Insulin Aspart is a fast-acting insulin analog used to treat diabetes mellitus, a metabolic disorder. It is used to control high blood sugar levels in adults and children with type 1 diabetes and adults with type 2 diabetes. Insulin Aspart is a recombinant human insulin analog that is produced by recombinant DNA technology. It is a short-acting insulin that is used to control post-meal blood sugar levels. It is usually taken before meals and can be used in combination with other diabetes    medications.
Insulin Aspart is part of the Endocrine and Metabolic Disorders Drugs market, which includes medications used to treat endocrine and metabolic disorders such as diabetes, thyroid disorders, and obesity. These drugs are used to control blood sugar levels, regulate hormones, and reduce the risk of complications associated with metabolic disorders.
Companies in the Insulin Aspart market include Novo Nordisk, Eli Lilly, Sanofi, and Merck. Show Less   Read more